Alpa Laboratorie
NSE: ALPA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Alpa Laboratorie's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alpa Laboratories Ltd is a pharmaceutical company that manufactures a diverse range of finished dosage forms for both human and veterinary applications. The company operates as both a branded manufacturer and a contract manufacturing partner for various domestic and multinational pharmaceutical firms.
Business Model
The company generates revenue through the production and sale of ethical, generic, and over-the-counter drugs. It leverages its WHO-GMP and ISO 9001:2000 certifications to provide manufacturing services for third-party clients alongside its own product portfolio.
- Incorporation Year:1988
Growth Outlook
Growth is driven by the expansion of its pharmaceutical finished dosage forms portfolio and the maintenance of international quality standards to attract further contract manufacturing partnerships.
Key Risks
- Regulatory Compliance. Failure to maintain WHO-GMP and ISO certifications could lead to the suspension of manufacturing operations or loss of export markets.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw chemicals can significantly impact profit margins.
- Competitive Pressure. The pharmaceutical sector is highly fragmented, leading to intense price competition in the generic and OTC drug segments.
Start your research today
Unlock AI insights, financials, peers and live data on Alpa Laboratorie and 5,000+ companies — free.
Key Metrics
REVENUE
₹106 Cr
TTM · consolidated
NET PROFIT
₹14 Cr
TTM · consolidated
EPS
₹6.78
TTM · consolidated
RETURN ON EQUITY
8.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
9.0%
TTM · consolidated
P/E
8.7x
Q4 FY26 · consolidated
EV/EBITDA
6.8x
Q4 FY26 · consolidated
EBITDA MARGIN
18.0%
TTM · consolidated
NET PROFIT MARGIN
1.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Alpa LaboratorieALPA | ₹127 Cr | 8.74 | 6.77 | -5.9% | 18.0% | 8.2% | 9.0% | -33.3% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Alpa Laboratorie
NSE: ALPA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Alpa Laboratorie's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alpa Laboratories Ltd is a pharmaceutical company that manufactures a diverse range of finished dosage forms for both human and veterinary applications. The company operates as both a branded manufacturer and a contract manufacturing partner for various domestic and multinational pharmaceutical firms.
Business Model
The company generates revenue through the production and sale of ethical, generic, and over-the-counter drugs. It leverages its WHO-GMP and ISO 9001:2000 certifications to provide manufacturing services for third-party clients alongside its own product portfolio.
- Incorporation Year:1988
Growth Outlook
Growth is driven by the expansion of its pharmaceutical finished dosage forms portfolio and the maintenance of international quality standards to attract further contract manufacturing partnerships.
Key Risks
- Regulatory Compliance. Failure to maintain WHO-GMP and ISO certifications could lead to the suspension of manufacturing operations or loss of export markets.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw chemicals can significantly impact profit margins.
- Competitive Pressure. The pharmaceutical sector is highly fragmented, leading to intense price competition in the generic and OTC drug segments.
Start your research today
Unlock AI insights, financials, peers and live data on Alpa Laboratorie and 5,000+ companies — free.
Key Metrics
REVENUE
₹106 Cr
TTM · consolidated
NET PROFIT
₹14 Cr
TTM · consolidated
EPS
₹6.78
TTM · consolidated
RETURN ON EQUITY
8.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
9.0%
TTM · consolidated
P/E
8.7x
Q4 FY26 · consolidated
EV/EBITDA
6.8x
Q4 FY26 · consolidated
EBITDA MARGIN
18.0%
TTM · consolidated
NET PROFIT MARGIN
1.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26